Compare Petróleo Brasileiro SA (PBR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Petróleo Brasileiro SA vs Recursion Pharmaceuticals Inc — how do they compare? Petróleo Brasileiro SA trades at $18.93 (market cap $112.59B), while Recursion Pharmaceuticals Inc trades at $3.01 (market cap $1.63B). The key difference: Petróleo Brasileiro SA is far larger — about 69.1× Recursion Pharmaceuticals Inc's market cap, and Petróleo Brasileiro SA pays a 9.51% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| PBR | RXRX | |
|---|---|---|
Market Cap | $112.59B | $1.63B |
Sector | Technology | Health |
52-Week High | $22.03 | $6.79 |
52-Week Low | $11.54 | $2.84 |
Enterprise Value | $176.05B | $1.05B |
Dividend Yield | 9.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PBR trades at $18.19, up 1.22% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a low P/E of 5.73 and robust profitability, including a 21.47% net income margin. Recent news highlights expansion in deepwater operations and strategic partnerships, while earnings have mostly beaten expectations except for a Q1 2026 miss.
The outlook is positive, supported by attractive valuation, solid cash flows, and dividend payments. Risks include oil price volatility and execution of new projects. Analyst consensus leans bullish with 50% buy ratings, but overbought RSI levels suggest near-term caution.
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
